Risk of hospitalizations associated with adverse effects of chemotherapy in a large community-based cohort of elderly women with ovarian cancer

International Journal of Gynecological Cancer

Volumn 19, Issue 8, 2009, Pages 1314-1321

  Nurgalieva, Zhannat ^a   Liu, Chih Chin ^a   Du, Xianglin L ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adverse effects; Chemotherapy; Hospitalization; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOMYOPATHY; COLITIS; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG FEVER; FEMALE; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVARY CANCER; PAROXYSMAL TACHYCARDIA; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; STOMATITIS; SYNCOPE; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HOSPITALIZATION; HUMANS; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RISK FACTORS; SEER PROGRAM; TREATMENT OUTCOME;

EID: 73349126703     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181b7662d     Document Type: Article

References (29)

1. Yancik R. Population aging and cancer: a cross-national concern. Cancer J. 2005;11:437-441.
2. Ozols RF. Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer. Cancer Invest. 2004;22:(suppl 2)11-20.
3. Markman M. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. Trends Pharmacol Sci. 2008;29:515-519.
4. Du XL, Sun CC, Milam MR, et al. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008; 18:660-669.
5. Graf C. Functional decline in hospitalized older adults. Am J Nurs. 2006;106:58-67.
6. Kleiner JM, Culakova E, Dale DC, et al. Risk factors for hospitalization in elderly cancer patients receiving chemotherapy. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 supplement). 2007:9035.
7. Cress RD, O'Malley CD, Leiserowitz GS, et al. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol. 2003;21:1530-1535.
8. Polsky D, Armstrong KA, Randall TC, et al. Variation in chemotherapy utilization in ovarian cancer: the relative contribution of geography. Health Serv Res. 2006;41:2201-2218.
9. Sundararajan V, Hershman D, Grann VR, et al. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol. 2002;20:173-178. (Pubitemid 34032609)
10. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute; 2008.
11. Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732-748.
12. National Cancer Institute. The SEER Program Code Manual (Revised Ed). Bethesda, MD: National Cancer Institute; 1994. NIH publication 94-1999.
13. Health Care Financing Administration. Data User Reference Guide (DURG). Baltimore, MD: Health Care Financing Administration; 2000.
14. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
15. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079.
16. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System. Cary, NC: SAS Institute, Inc; 1997.
17. Husain A, Aptaker L, Spriggs DR, et al. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol. 1998;71:104-107.
18. Chiara S, Conte P, Franzone P, et al. High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. Am J Clin Oncol. 1994;17:72-76.
19. Rose PG, Piver MS. Intestinal perforation secondary to paclitaxel. Gynecol Oncol. 1995;57:270-272.
20. Feenstra J, Vermeer RJ, Stricker BH. Fatal hepatic coma attributed to paclitaxel. J Natl Cancer Inst. 1997;89:582-583.
21. Bennett CL, Calhoun EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist. 2007;12: 478-483.
22. Hortobagyi GN, Buzdar AU, Marcus CE, et al. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986;1:105-109.
23. Sharma S, Rezai K, Driscoll D, et al. Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2006;103:181-185.
24. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96: 1682-1691.
25. Marsh S, Paul J, King CR, et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol. 2007;25:4528-4535.
26. Wadler S, Yeap B, Vogl S, et al. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term resultsVEastern Cooperative Oncology Group Study E2878. Cancer. 1996;77:733-742.
27. Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14:195-208.
28. Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol. 1994;12:2301-2308. (Pubitemid 24346699)
29. Fader AN, von Gruenigen V, Gibbons H, et al. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol. 2008;109:33-38.